Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Modalis Therapeutics Corporation ( (JP:4883) ) has shared an announcement.
Modalis Therapeutics Corporation has completed the pay-in procedures for the issuance of 700 new common shares as part of a restricted-stock-based remuneration plan for its subsidiary employees. This move, resolved by the Board of Directors, aims to incentivize and retain key personnel, potentially strengthening the company’s operational capabilities and market position.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a biotechnology company listed on the Tokyo Stock Exchange, focusing on developing innovative therapeutics. The company is involved in the creation and commercialization of gene therapy solutions, targeting rare genetic disorders.
Average Trading Volume: 4,503,377
Technical Sentiment Signal: Sell
Current Market Cap: Yen6.46B
For detailed information about 4883 stock, go to TipRanks’ Stock Analysis page.